[Halving Time of <i>BCR-ABL</i> Transcripts as a Precise Predictor for Deep Molecular Response in Patients with Chronic Myeloid Leukemia Treated with TKI].
In addition to <i>BCR-ABL</i><sup>IS</sup> level, HT of <i>BCR-ABL</i><sup>IS</sup> can be used as another important predictor of treatment efficacy in CML patients. The combination of <i>BCR-ABL</i><sup>IS</sup> level and HT has a more accurate predictive value for long-term molecular response of CML patients after TKI treatment.
Authors
- Lixia Cao (ORCID: https://orcid.org/0000-0001-6942-1565)
- Yanqiu Han (ORCID: https://orcid.org/0000-0002-2658-0803)
- Huijuan Ren
- Lan Yang (ORCID: https://orcid.org/0009-0001-2506-2131)
Institutions
- Inner Mongolia Medical University (CN)
Publication Details
- Journal
- PubMed
- Published
- 2024-10-01
- DOI
- https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.05.007
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article